MedPath

Clinical evaluation of irAEs in ptients with ICI

Not Applicable
Conditions
immune related adverse events
Registration Number
JPRN-UMIN000037931
Lead Sponsor
Toho University School of Medicine
Brief Summary

Compared to the non-diabetes, diabetes has not been associated with irAEs risks for baseline characteristics and after propensity score matching analysis. During a mean follow-up of 30 months, overall (OS) and cancer specific progression free survival (PFS) were significantly improved in irAEs group. After propensity scores analyses, DM was significantly associated with increased risks of lower OS.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
88
Inclusion Criteria

Not provided

Exclusion Criteria

nothing

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath